A web‐based registry of inherited bleeding disorders in the region of Emilia‐Romagna: results at three and a half years

Summary.  A Registry of inherited bleeding disorders was set up in the Region of Emilia‐Romagna (RER) to collect information about these diseases and to improve the quality of care. From January 2003, the eight Haemophilia Centres (HC) in the RER began to use computerized clinical records; every 6 months, they send data to Parma Hospital to be processed and published in a website (http://www.registroemofiliarer.it). Great efforts are made to ensure high quality of data. Results of general interest are included in a free ‘public area’ and more sensitive data in a ‘reserved area’ (open only to HC and to health authorities). A total of 610 individuals are included: 249 haemophilia A (HA), 63 haemophilia B (HB), 173 von Willebrand’s disease, 69 rare bleeding disorders, seven platelet disorders and 49 haemophilia carriers; 131 were genotyped, 188 were tested for inhibitors (16 affected). The most frequent bleeding was haemarthrosis. The joint score (evaluated in 104 haemophiliacs) was higher in severe HA. There were 22 HIV‐positive and 182 hepatitis C virus‐positive patients (21% have chronic hepatitis, two hepatocellular carcinoma). In 2005, two patients received primary prophylaxis, 47 secondary prophylaxis, four children were on immune‐tolerance induction. From 2003 to 2005 the use of recombinant products was greatly increased and the majority of patients received them. The mean clotting factor consumption for prophylaxis was higher than on‐demand treatment. The main features of registry are to collect high quality and comprehensive data of all patients followed by HC, to improve quality of care and it’s availability on the web.

[1]  H. Lenk The German Registry of immune tolerance treatment in hemophilia--1999 update. , 2000, Haematologica.

[2]  Massimo Pandolfo,et al.  Molecular Basis , 2022 .

[3]  G. Mariani,et al.  International Immune Tolerance Registry, 1997 Update , 1999, Vox Sanguinis.

[4]  C. Kessler,et al.  The molecular basis of haemophilia B , 1998, Haemophilia : the official journal of the World Federation of Hemophilia.

[5]  J. Oldenburg,et al.  Haemophilia A: from mutation analysis to new therapies , 2005, Nature Reviews Genetics.

[6]  C. F. Bryan,et al.  Annual Report 2006 , 2007 .

[7]  J. Batlle,et al.  Immune tolerance treatment in haemophilia patients with inhibitors: the Spanish Registry , 2001, Haemophilia : the official journal of the World Federation of Hemophilia.

[8]  Mannucci,et al.  Optimising local therapy during oral surgery in patients with von Willebrand disease: effective results from a retrospective analysis of 63 cases , 2000, Haemophilia : the official journal of the World Federation of Hemophilia.

[9]  J. Katz,et al.  The North American Immune Tolerance Registry: Practices, Outcomes, Outcome Predictors , 2002, Thrombosis and Haemostasis.

[10]  A. Gogh The impact of information technology. , 1997, Caring : National Association for Home Care magazine.

[11]  D. Green The management of acquired haemophilia , 2006 .

[12]  R. I. Baker,et al.  The impact of information technology on haemophilia care , 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

[13]  D. Dimichele,et al.  Rare Bleeding Disorder Registry: deficiencies of factors II, V, VII, X, XIII, fibrinogen and dysfibrinogenemias , 2004, Journal of Thrombosis and Haemostasis.

[14]  C. Müller,et al.  Lithuanian haemophilia A and B registry comprising phenotypic and genotypic data , 2001, British journal of haematology.

[15]  P. Giangrande,et al.  Treatment of haemophilia in the United Kingdom 1981-1996. , 2001 .

[16]  S. Darby,et al.  The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977–99 , 2004, Journal of thrombosis and haemostasis : JTH.

[17]  M. Poon Hemophilia and von Willebrand's disease: 1. Diagnosis, comprehensive care and assessment. Association of Hemophilia Clinic Directors of Canada. , 1995, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[18]  G. Lippi,et al.  The natural history of chronic hepatitis C in a cohort of HIV-negative Italian patients with hereditary bleeding disorders. , 2001, Blood.

[19]  S. Schulman Continuous Infusion of Recombinant Factor VIIa in Hemophilic Patients with Inhibitors: Safety, Monitoring, and Cost Effectiveness , 2000, Seminars in thrombosis and hemostasis.

[20]  Sumon YusufPhotoshare Care , 1890, The Hospital.